Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center.

December 20, 2021 — Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center

The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers. However, since UV light, which is needed to activate 8-MOP, cannot penetrate through tissue, it has not been possible to use 8-MOP to treat solid tumors.  Immunolight's X-PACT system solves this problem.  Innovative Immunolight phosphor materials convert tissue penetrating energies, such as low dose X-ray, into UV light inside solid tumors in the body.  These energy converting phosphors are injected along with 8-MOP into the solid tumor, and low dose x-ray energy is applied at the site.  The phosphors convert the x-ray into UV light which activates the 8-MOP inside the solid tumor to kill the cancer.

More details about the Phase 1 trial and eligibility criteria can be found here

Immunolight founder and CEO Rick Bourke commented, "We are thrilled to start patient recruitment and begin this Phase 1 trial, bringing our innovative technology to fruition in treating cancer and starting what we believe is a new era in cancer treatment."

This milestone is the culmination of over 13 years of intense research and development in partnership with Duke University and Duke Medical Center where a team of over 30 scientists, physicians and engineers has been active.  "From day one, our highest priority has been to translate this amazing science into a paradigm changing cancer treatment in patients," President Harold Walder said. "We are so excited to take this next step to get the treatment into the clinic." 

For more information: www.immunolight.com

Related Content

News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — Representatives from the Diagnostics Working Group of the IASLC Early Detection and Screening Committee ...

Time August 08, 2022
arrow
News | Lung Imaging

August 8, 2022 — A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill ...

Time August 08, 2022
arrow
News | Proton Therapy

August 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, Fred ...

Time August 05, 2022
arrow
News | Radiology Business

August 4, 2022 — The Biden Administration, through the U.S. Department of Health and Human Services and the Centers for ...

Time August 04, 2022
arrow
News | Pediatric Imaging

August 3, 2022 — The Jack Martin Fund (JMF) has built on its partnership with the Mount Sinai Health System to provide ...

Time August 03, 2022
arrow
Feature | Oncology Information Management Systems (OIMS)

August 2, 2022 — The oncology information systems market is projected to be worth $2.59 Bn by 2022 and is expected to ...

Time August 02, 2022
arrow
Feature | Lung Imaging

August 1, 2022 — In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources ...

Time August 01, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
Subscribe Now